Nya data som presenteras på årets ASCO-GU bekräftar BAVENCIO (avelumab) position som första linjens underhållsbehandling för patienter med lokalt avancerad eller metastaserad urotelial cancer.
Läs mer...In collaboration with one of Europe’s leading biotechnology clusters, BioM, in Germany, SmiLe now launches a new, international training program, BioTech Bootcamp. The program, which is sponsored by Merck, a global leader in pharmaceuticals and life science technology, is based on SmiLe’s successful Bootcamp concept and is tailored for future entrepreneurs who want to develop and commercialize their business ideas in biotechnology.
Läs mer...
